AbbVie Inc. (NYSE:ABBV) stock has decreased today as analysts trimmed near-term earnings forecasts and geopolitical risks resurfaced, despite positive developments around acquisitions, pipeline expansion, and target price revisions.
Positive Sentiment:
Leerink Partners maintained a Buy rating with a $210 price target on AbbVie.
AbbVie Buy Rating Supported by Strong Performance, Growth Prospects, and Strategic Positioning
Positive Sentiment:
Leerink Partners raised its FY2026 EPS estimate to $14.03, up slightly from $14.01.
Leerink Partnrs Issues Positive Outlook for AbbVie Earnings
Positive Sentiment:
Brokerages set AbbVie's target price at $211.29, signaling bullish analyst expectations.
Brokerages Set AbbVie Inc. (NYSE:ABBV) Target Price at $211.29
Positive Sentiment:
AbbVie agreed to acquire Capstan Therapeutics for $2.1 billion to bolster its autoimmune pipeline.
AbbVie to Acquire Capstan Therapeutics for $2.1B, Boosting Autoimmune Pipeline
Neutral Sentiment:
Analysts preview expectations for AbbVie's upcoming Q2 earnings.
Here's What to Expect From AbbVie's Next Earnings Report
Neutral Sentiment:
Discussion of how Skyrizi and Rinvoq sales may offset Humira's decline in Q2.
How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?
Neutral Sentiment:
Comparative survey conducted between AbbVie and Bayer.
Head-To-Head Survey: AbbVie (NYSE:ABBV) and Bayer Aktiengesellschaft (OTCMKTS:BAYRY)
Negative Sentiment:
Leerink Partners cut AbbVie's Q2 2025 EPS forecast to $2.87 from $3.24.
Leerink Partnrs Has Bearish Forecast for AbbVie Q2 Earnings
Negative Sentiment:
President Trump threatened to impose up to 200% tariffs on imported pharmaceuticals, heightening sector uncertainty.
Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
Posted 41m ago
AI Generated. May Contain Errors.